BG105881A - L-арабино-дизахариди на антрациклини, методи за тяхното получаване и фармацевтични състави, които ги съдържат - Google Patents
L-арабино-дизахариди на антрациклини, методи за тяхното получаване и фармацевтични състави, които ги съдържат Download PDFInfo
- Publication number
- BG105881A BG105881A BG105881A BG10588101A BG105881A BG 105881 A BG105881 A BG 105881A BG 105881 A BG105881 A BG 105881A BG 10588101 A BG10588101 A BG 10588101A BG 105881 A BG105881 A BG 105881A
- Authority
- BG
- Bulgaria
- Prior art keywords
- formula
- group
- compounds
- hexopyranosyl
- pharmaceutically acceptable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract 5
- 229940045799 anthracyclines and related substance Drugs 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- -1 acetyl- Chemical group 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 231100000259 cardiotoxicity Toxicity 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 4
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000000837 carbohydrate group Chemical group 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000000600 disaccharide group Chemical group 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 4
- MWROBUNHUAIFQH-YBTHPKLGSA-N (7s,9s)-6,7,9,11-tetrahydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C1[C@@H](O)C[C@@](C(=O)CO)(O)CC1=C2O MWROBUNHUAIFQH-YBTHPKLGSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005858 glycosidation reaction Methods 0.000 description 3
- 229910001510 metal chloride Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- KAHVZNKZQFSBFW-UHFFFAOYSA-N n-methyl-n-trimethylsilylmethanamine Chemical compound CN(C)[Si](C)(C)C KAHVZNKZQFSBFW-UHFFFAOYSA-N 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical group [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- QHUNJMXHQHHWQP-UHFFFAOYSA-N trimethylsilyl acetate Chemical compound CC(=O)O[Si](C)(C)C QHUNJMXHQHHWQP-UHFFFAOYSA-N 0.000 description 1
- HMBPRCCUFZTWRS-UHFFFAOYSA-N trimethylsilyl fluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)CF HMBPRCCUFZTWRS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999FI000043A IT1307846B1 (it) | 1999-03-09 | 1999-03-09 | L-arabino disaccaridi di antracicline, loro processi di preparazione ecomposizioni farmaceutiche che li contengono. |
| PCT/EP2000/002006 WO2000053615A1 (en) | 1999-03-09 | 2000-03-08 | L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105881A true BG105881A (bg) | 2002-06-28 |
Family
ID=11352829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105881A BG105881A (bg) | 1999-03-09 | 2001-09-05 | L-арабино-дизахариди на антрациклини, методи за тяхното получаване и фармацевтични състави, които ги съдържат |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6653289B1 (pt) |
| EP (1) | EP1169327B1 (pt) |
| JP (1) | JP2002539133A (pt) |
| KR (1) | KR20010105368A (pt) |
| CN (1) | CN1150201C (pt) |
| AR (1) | AR042571A1 (pt) |
| AT (1) | ATE311398T1 (pt) |
| AU (1) | AU3554500A (pt) |
| BG (1) | BG105881A (pt) |
| BR (1) | BR0008798A (pt) |
| CA (1) | CA2366675A1 (pt) |
| CZ (1) | CZ296359B6 (pt) |
| DE (1) | DE60024428D1 (pt) |
| EA (1) | EA003455B1 (pt) |
| EE (1) | EE200100474A (pt) |
| HU (1) | HUP0200208A3 (pt) |
| IT (1) | IT1307846B1 (pt) |
| MX (1) | MXPA01009025A (pt) |
| PL (1) | PL353169A1 (pt) |
| SK (1) | SK12802001A3 (pt) |
| TR (1) | TR200102584T2 (pt) |
| UA (1) | UA69446C2 (pt) |
| WO (1) | WO2000053615A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006124720A1 (en) * | 2005-05-12 | 2006-11-23 | The Ohio State University Research Foundation | Multidrug resistant anticancer anthracyclines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262565B (it) * | 1993-09-30 | 1996-07-04 | Menarini Farma Ind | Disaccaridi di antracicline, loro processi di preparazione e composizioni farmaceutiche che li contengono. |
-
1999
- 1999-03-09 IT IT1999FI000043A patent/IT1307846B1/it active
-
2000
- 2000-03-08 EE EEP200100474A patent/EE200100474A/xx unknown
- 2000-03-08 US US09/914,987 patent/US6653289B1/en not_active Expired - Fee Related
- 2000-03-08 DE DE60024428T patent/DE60024428D1/de not_active Expired - Lifetime
- 2000-03-08 CA CA002366675A patent/CA2366675A1/en not_active Abandoned
- 2000-03-08 BR BR0008798-0A patent/BR0008798A/pt not_active IP Right Cessation
- 2000-03-08 SK SK1280-2001A patent/SK12802001A3/sk unknown
- 2000-03-08 WO PCT/EP2000/002006 patent/WO2000053615A1/en not_active Application Discontinuation
- 2000-03-08 AU AU35545/00A patent/AU3554500A/en not_active Abandoned
- 2000-03-08 AT AT00914117T patent/ATE311398T1/de not_active IP Right Cessation
- 2000-03-08 TR TR2001/02584T patent/TR200102584T2/xx unknown
- 2000-03-08 JP JP2000604050A patent/JP2002539133A/ja active Pending
- 2000-03-08 HU HU0200208A patent/HUP0200208A3/hu unknown
- 2000-03-08 CZ CZ20013228A patent/CZ296359B6/cs not_active IP Right Cessation
- 2000-03-08 CN CNB008046808A patent/CN1150201C/zh not_active Expired - Fee Related
- 2000-03-08 MX MXPA01009025A patent/MXPA01009025A/es unknown
- 2000-03-08 KR KR1020017011178A patent/KR20010105368A/ko not_active Application Discontinuation
- 2000-03-08 PL PL00353169A patent/PL353169A1/xx unknown
- 2000-03-08 EA EA200100953A patent/EA003455B1/ru not_active IP Right Cessation
- 2000-03-08 EP EP00914117A patent/EP1169327B1/en not_active Expired - Lifetime
- 2000-03-09 AR ARP000101041A patent/AR042571A1/es unknown
- 2000-08-03 UA UA2001106843A patent/UA69446C2/uk unknown
-
2001
- 2001-09-05 BG BG105881A patent/BG105881A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1169327A1 (en) | 2002-01-09 |
| PL353169A1 (en) | 2003-11-03 |
| EE200100474A (et) | 2002-12-16 |
| TR200102584T2 (tr) | 2002-03-21 |
| JP2002539133A (ja) | 2002-11-19 |
| KR20010105368A (ko) | 2001-11-28 |
| HUP0200208A3 (en) | 2003-08-28 |
| BR0008798A (pt) | 2001-12-26 |
| ITFI990043A1 (it) | 2000-09-09 |
| SK12802001A3 (sk) | 2002-01-07 |
| HUP0200208A2 (hu) | 2002-05-29 |
| CZ296359B6 (cs) | 2006-02-15 |
| EA003455B1 (ru) | 2003-06-26 |
| CN1150201C (zh) | 2004-05-19 |
| IT1307846B1 (it) | 2001-11-19 |
| WO2000053615A1 (en) | 2000-09-14 |
| AU3554500A (en) | 2000-09-28 |
| CN1343214A (zh) | 2002-04-03 |
| MXPA01009025A (es) | 2002-10-23 |
| DE60024428D1 (de) | 2006-01-05 |
| EP1169327B1 (en) | 2005-11-30 |
| CZ20013228A3 (cs) | 2002-02-13 |
| UA69446C2 (uk) | 2004-09-15 |
| CA2366675A1 (en) | 2000-09-14 |
| US6653289B1 (en) | 2003-11-25 |
| ITFI990043A0 (it) | 1999-03-09 |
| AR042571A1 (es) | 2005-06-29 |
| EA200100953A1 (ru) | 2002-02-28 |
| ATE311398T1 (de) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5304687A (en) | Morpholinyl derivatives of doxorubicin and process for their preparation | |
| JPS6260395B2 (pt) | ||
| US4684629A (en) | 3'-deamino-3'-hydroxy-4'-deoxy-4'-amino doxorubicin and related daunorubicin | |
| BG105881A (bg) | L-арабино-дизахариди на антрациклини, методи за тяхното получаване и фармацевтични състави, които ги съдържат | |
| US5801152A (en) | Antracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them | |
| KR100456088B1 (ko) | 5-이미노-13-데옥시 안트라시클린 유도체와 그 이용 및 그제조방법 | |
| CZ451299A3 (cs) | 13-Dihydro-3'aziridino anthracykliny | |
| NZ203047A (en) | Daunorubicin and doxorubicin analogues and pharmaceutical compositions | |
| JPH05247080A (ja) | 新規アントラサイクリン系抗生物質 | |
| SI8210860A8 (sl) | Postopek za pripravo 4’-jodo derivatov antraciklinskih glikozidov | |
| SK415191A3 (sk) | Antracyklínglykozidy, spôsob ich prípravy a farmaceutický prostriedok, ktorý ich obsahuje |